Post Marketing Observational Study to Describe the Effectiveness and Safety of Venetoclax Treatment in Chronic Lymphocytic Leukemia (CLL) Patients in Routine Clinical Practice
Phase of Trial: Phase IV
Latest Information Update: 21 Feb 2019
Price : $35 *
At a glance
- Drugs Venetoclax (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- Acronyms REVEAL
- Sponsors AbbVie
- 13 Feb 2019 Planned number of patients changed from 67 to 66.
- 13 Feb 2019 Status changed from not yet recruiting to recruiting.
- 06 Nov 2018 Planned initiation date changed from 31 Oct 2018 to 15 Jan 2019.